Skip to content

Evaluation of the Colonoscope With Vision to 330 ° (Full Spectrum Endoscopy) in the Detection of Colorectal Adenomas

Evaluation of the Colonoscope With Vision to 330 ° (Full Spectrum Endoscopy) in the Detection of Colorectal Adenomas

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02859870
Acronym
FUSETM-Colon
Enrollment
141
Registered
2016-08-09
Start date
2015-03-18
Completion date
2016-04-30
Last updated
2017-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Adenoma

Brief summary

The coloscopy is considered as the gold standard for screening and resection of colorectal adenomas. However the literature reports that the rate of omitted adenoma is still high (24 to 41%). The development of the FUSE system (Endochoice, USA) allows a larger field of view with a projection onto 3 screens (330° vision). A pilot study and a randomized multicentre has demonstrated the feasibility with a significant improvement of the rate of detected adenomas. This first study in France concerning this technology has the objectives to demonstrate the feasibility in France, the safety and to compare the rate of detected adenomas with data of the literature.

Interventions

DEVICEFUSE-TM colonoscope

Colonoscopy in conditions of normal security including patient clinical examination before leaving the hospital. Data collection by each operator.

Sponsors

Institut Paoli-Calmettes
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age \>18 years * Diagnostic colonoscopy

Exclusion criteria

* Colorectal cancer * Colic surgery * Preparation of average or poor quality * Rectal polyp of hyperplastic type \<2 mm

Design outcomes

Primary

MeasureTime frameDescription
Efficacy1 dayCecal intubation rate

Secondary

MeasureTime frameDescription
Toxicity1 daySerious adverse events (perforation, uncontrolled bleeding)

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026